Clinical trials for recurrent glioblastoma are active at major Austrian medical universities and specialized oncology centers. Research focuses on personalized targeted therapies, advanced surgical resection protocols, and asunercept efficacy. Access is primarily managed through the Medical University of Vienna and University Hospital Innsbruck.
- Targeted therapy: The ATTRACT trial provides personalized drugs based on ex vivo screening.
- Surgical research: Studies compare tumor resection plus adjuvant therapy against second-line treatment alone.
- Immunotherapy access: Multi-site trials evaluate asunercept combined with radiotherapy for first or second relapses.
- Radiation protocols: Phase 3 trials assess adding re-irradiation to standard lomustine for improved survival.
Bookimed Expert Insight: Patients should focus on clinics like Wiener Privatklinik or Vienna General Hospital (AKH) where professors from the Medical University of Vienna practice. These institutions maintain over 42 specialized university hospitals and institutes. Dr. Wolfgang Köstler at Wiener Privatklinik offers specific expertise in individualized cancer treatment and molecular oncology research. This academic connection provides a direct bridge to trials that private facilities alone may lack.
Patient Consensus: Patients note that trial windows are narrow and recommend searching international databases like ClinicalTrials.gov early. Many emphasize the need to ask oncologists about cross-border options in Germany or Switzerland when local immunotherapy trials are limited.